Laurion Capital Management’s Praxis Precision Medicines PRAX Stock Holding History

Laurion Capital Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-225,000	Closed	-$13.7M	–	721
2024 Q1	$13.7M	Buy	+225,000	New	+$10.1M	0.12%	157
2023 Q1	–	Sell	-13,111	Closed	-$468K	–	503
2022 Q4	$468K	Sell	13,111 -96	-0.7%	-$2.99K	﹤0.01%	358
2022 Q3	$450K	Sell	13,207 -19,238	-59%	-$959K	﹤0.01%	406
2022 Q2	$1.19M	Sell	32,445 -3,914	-11%	-$418K	0.02%	264
2022 Q1	$5.57M	Sell	36,359 -480	-1%	-$98.6K	0.07%	155
2021 Q4	$10.9M	Buy	36,839 +3,867	+12%	+$1.13M	0.11%	123
2021 Q3	$9.14M	Buy	32,972 +61	+0.2%	+$16.5K	0.04%	285
2021 Q2	$9.02M	Buy	32,911 +29,578	+887%	+$10.6M	0.05%	226
2021 Q1	$1.64M	Hold	3,333	–	–	0.01%	446
2020 Q4	$2.75M	Buy	+3,333	New	+$1.95M	0.02%	312

Other funds holding PRAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Laurion Capital Management's PRAX Position: Q2 2024 in Review

Laurion Capital Management sold out of Praxis Precision Medicines (PRAX) in Q2 2024, closing a stake of 225,000 shares — an estimated $13.7M sold.

Laurion Capital Management first reported a position in PRAX in Q4 2020 and held it in 10 quarters. The position peaked at $13.7M in Q1 2024. 113 funds tracked by Wall St. Rank hold PRAX as of Q2 2024.

Laurion Capital Management reported no remaining Praxis Precision Medicines position as of Q2 2024 after selling out during the quarter.
Laurion Capital Management sold 225,000 Praxis Precision Medicines shares in Q2 2024, an estimated $13.7M.
Laurion Capital Management first reported a position in Praxis Precision Medicines in Q4 2020 and held it in 10 quarters.
Laurion Capital Management's Praxis Precision Medicines position peaked at $13.7M in Q1 2024.
113 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2024.

Based on Laurion Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.